|Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer|
T André, C Boni, L Mounedji-Boudiaf, M Navarro, J Tabernero, T Hickish, ...
New England Journal of Medicine 350 (23), 2343-2351, 2004
|FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study|
C Tournigand, T André, E Achille, G Lledo, M Flesh, D Mery-Mignard, ...
Journal of Clinical Oncology 22 (2), 229-237, 2004
|Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial|
T André, C Boni, M Navarro, J Tabernero, T Hickish, C Topham, A Bonetti, ...
Journal of Clinical Oncology 27 (19), 3109-3116, 2009
|KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab|
A Lievre, JB Bachet, V Boige, A Cayre, D Le Corre, E Buc, M Ychou, ...
Journal of clinical oncology 26 (3), 374-379, 2008
|Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial|
C Louvet, R Labianca, P Hammel, G Lledo, MG Zampino, T Andre, ...
Journal of Clinical Oncology 23 (15), 3509-3516, 2005
|Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with …|
M Peeters, T Jay Price
JOURNAL OF CLINICAL ONCOLOGY, 2010
|Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial|
J Bennouna, J Sastre, D Arnold, P Österlund, R Greil, E Van Cutsem, ...
The lancet oncology 14 (1), 29-37, 2013
|OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer—a GERCOR study|
C Tournigand, A Cervantes, A Figer, G Lledo, M Flesch, M Buyse, ...
Journal of clinical oncology 24 (3), 394-400, 2006
|Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials|
DJ Sargent, HS Wieand, DG Haller, R Gray, JK Benedetti, M Buyse, ...
Journal of Clinical Oncology 23 (34), 8664-8670, 2005
|Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study|
MJ Overman, R McDermott, JL Leach, S Lonardi, HJ Lenz, MA Morse, ...
The Lancet Oncology 18 (9), 1182-1191, 2017
|Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients|
C Louvet, T Andre, JM Tigaud, E Gamelin, JY Douillard, R Brunet, ...
Journal of Clinical Oncology 20 (23), 4543-4548, 2002
|Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies|
F Huguet, T André, P Hammel, P Artru, J Balosso, F Selle, ...
Journal of Clinical Oncology 25 (3), 326-331, 2007
|Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer|
A De Gramont, J Vignoud, C Tournigand, C Louvet, T Andre, C Varette, ...
European journal of Cancer 33 (2), 214-219, 1997
|Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer|
RM Goldberg, I Tabah-Fisch, H Bleiberg, A De Gramont, C Tournigand, ...
Journal of Clinical Oncology 24 (25), 4085-4091, 2006
|Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3|
E Van Cutsem, R Labianca, G Bodoky, C Barone, E Aranda, B Nordlinger, ...
Journal of Clinical Oncology 27 (19), 3117-3125, 2009
|Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial|
A de Gramont, E Van Cutsem, HJ Schmoll, J Tabernero, S Clarke, ...
The lancet oncology 13 (12), 1225-1233, 2012
|Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials|
D Sargent, A Sobrero, A Grothey, MJ O'Connell, M Buyse, T Andre, ...
Journal of Clinical Oncology 27 (6), 872, 2009
|Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study|
B Chibaudel, F Maindrault-Goebel, G Lledo, L Mineur, T André, ...
Journal of clinical oncology 27 (34), 5727, 2009
|Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib …|
P Hammel, F Huguet, JL van Laethem, D Goldstein, B Glimelius, P Artru, ...
Jama 315 (17), 1844-1853, 2016
|Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study|
T Andre, C Tournigand, O Rosmorduc, S Provent, F Maindrault-Goebel, ...
Annals of Oncology 15 (9), 1339-1343, 2004